Zanaflex (tizanidine) from Acorda Therapeutics is a short-acting drug used to manage spasticity associated with multiple sclerosis and spinal cord injury. It blocks nerve impulses (pain sensations) that are sent to the brain. Because of its temporary effect, treatment with tizanidine should be reserved for moments when spasticity relief is most important.

Its mechanism of action leads to spasticity reduction by blocking nerve impulses through pre-synaptic inhibition of motor neurons — without reducing muscle strength.

Tizanidine tablets or capsules should be taken by mouth with an initial dosage of 2 mg three times a day. For maintenance, a 2 to 4 mg increase may be prescribed at each dose until satisfactory reduction of muscle spasms is achieved — up to a maximum dose of 36 mg per day.

Most common side effects may include dry mouth, drowsiness, dizziness, asthenia, or infection.

Significant interactions can occur with tizanidine and other medicines, nutritional supplements, and certain herbal products. Patients should confer with their healthcare provider to ensure safe use.

Zanaflex is  available as a generic medicine. The generic is sold at lower prices than the brand name product.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Sativex, Cannabis Extract for MS Spasticity, Now Available to Select Patients in England

The cannabis sativa plant extract Sativex is a cost-effective therapy for spasticity in multiple sclerosis (MS) and can be offered to patients in England needing it on at least a monthlong trial basis, the National Institute for Health and Care Excellence (NICE) said in issuing a final recommendation on the treatment. This decision reverses a previous draft guidance that […]

‘Soothie Cushion’ Designed to Regulate Body Temperature in Travelers With MS, Other Disabilities

Newly launched, the Soothie Cushion is designed to provide seating comfort and help regulate the body temperature of travelers with disabilities, including multiple sclerosis (MS) and myasthenia gravis, says its official retailer, Special Needs Group/Special Needs at Sea (SNG). The product is said to offer enduring comfort to wheelchair users through hot and cold therapy. What […]

#ECTRIMS2019 – Mollii Suit Can Ease Muscle Stiffness and Improve Movement, Reports State

Mollii, an electrostimulation suit, can help reduce muscle stiffness, or spasticity, and its associated pain, as well as improve muscle activation in people with multiple sclerosis (MS), cerebral palsy, stroke, and other neurological injuries, according to Inerventions, the Swedish company that developed and markets it. With a few hours of weekly treatment people report better control […]

MS News that Caught My Eye Last Week: Dark Rimmed Lesions, Sativex in the UK, NHS Care Toolkit for Neurological Diseases, Wahls Diet

Dark Rimmed Brain Lesions May Be Signal of Aggressive Disease, NIH Study Says Researchers in this study found that specific brain lesions, notable for their dark rims, may indicate that a patient’s multiple sclerosis is likely to progress quickly. They suggest that early detection of these lesions can help doctors to decide to begin aggressive […]

NICE and NHS England Oppose Sativex to Treat Spasticity in MS, Urge More Studies of Medical Cannabis

A draft guidance issued by the National Institute for Health and Care Excellence (NICE), a U.K. advisory board, and a review by England’s National Health Service (NHS) call for more research into medical cannabis for multiple sclerosis and other conditions. NICE also recommended against prescribing Sativex as a treatment for spasticity (muscle stiffness) in people with  MS for reasons related […]

My Pain Is Real — Don’t Deny Me Relief

I am quite outspoken. I have no problem voicing my opinion or needs — or so I thought. An exchange this morning left me speechless. While my head was swimming with semi-intelligible responses, I was rendered mute. Let me just say that I have been on pain medication for a long while. I receive my […]

PathMaker Neurosystems Wins France’s Top Prize for Innovation for Spasticity Treatment

The developer of an innovative, first-in-class, noninvasive device for the treatment of spasticity in multiple sclerosis (MS) and other conditions has won the 2019 CCI France International Trophy for Innovation. PathMaker Neurosystems was selected from a list of eight finalist companies, which were distinguished among 150 nominees from 40 countries and across all technology sectors, […]

Less-frequent Dosing with Arbaclofen ER Tablets Decreases Spasticity As Well As Standard Baclofen, MS Trial Data Show

Arbaclofen extended-release (ER) tablets taken twice a day can effectively reduce spasticity (muscle stiffness) in patients with multiple sclerosis (MS) with similar potency to that of standard and more-frequently-dosed baclofen (brand name Lioresal), Phase 3 clinical trials show. Latest trial data were presented in two posters during the 33rd Annual Meeting of the Consortium of Multiple Sclerosis Centers […]

FDA Approves Botox to Treat Upper Limb Spasticity in Children Aged 2 to 17

The U.S. Food and Drug Administration (FDA) has approved the use of Botox (onabotulinumtoxinA), marketed by Allergan, for the treatment of children ages 2 to 17 with upper limb muscle stiffness or spasticity, a common symptom in children with multiple sclerosis (MS). The agency is still reviewing the use of Botox for treating lower limb spasticity […]